10-K: enGene Holdings Reports FY2025 Losses, Advances Bladder Cancer Therapy

enGene Holdings Inc. reported increased net losses for fiscal year 2025 while advancing its lead bladder cancer therapy, detalimogene, towards a planned BLA submission in late 2026.

Summary

• enGene Holdings Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for mucosal tissues, with its lead product candidate, detalimogene voraplasmid (formerly EG-70), targeting non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
• The company reported a net loss of $117.3 million for the fiscal year ended October 31, 2025, a significant increase from $55.1 million in the prior fiscal year, bringing the accumulated deficit to $372.0 million.
• Research and development expenses increased by $56.2 million to $94.5 million in FY2025, primarily due to increased detalimogene manufacturing activities in preparation for a planned Biologics License Application (BLA) submission and increased clinical operations.
• Preliminary Phase 2 data from the LEGEND study (Cohort 1, Post-Protocol Amendment Patients, October 24, 2025 cut-off) showed 62% of patients remained in complete response (CR) at six months, with all evaluable patients at nine months also demonstrating continued CR.
• However, preliminary efficacy data for Pre-Protocol Amendment Patients in the LEGEND study showed a markedly lower 12-month CR rate compared to FDA-approved products for BCG-unresponsive NMIBC patients.
• Detalimogene has received FDA Regenerative Medicines Advanced Therapy (RMAT) and Fast Track designations, and the LEGEND study is part of the FDA's Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program.
• The company plans to file a BLA with the FDA in the second half of 2026 for approval to market detalimogene in the United States as a monotherapy for BCG-unresponsive NMIBC with CIS.
• As of October 31, 2025, cash, cash equivalents, and marketable securities totaled $202.3 million. Subsequent to this date, the company raised approximately $140.1 million net from a public offering in November 2025.
• Material weaknesses in internal control over financial reporting identified in prior years have been remediated as of October 31, 2025.

Sentiment

Score: 4

Explanation: While the company shows promising clinical data for its lead candidate under an amended protocol and has successfully raised capital, the significant increase in net losses, high cash burn, and the historical underperformance of the drug under the old protocol (Pre-Protocol Amendment Patients) indicate substantial financial and clinical risks. The heavy dependence on a single product candidate and the early stage of other programs also contribute to a cautious outlook.

Positives

• Detalimogene has received FDA Regenerative Medicines Advanced Therapy (RMAT) and Fast Track designations, which are intended to expedite development and review.
• The LEGEND study has been selected for the FDA's Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program, aiming to accelerate development by increasing communication with the FDA.
• Preliminary Phase 2 data for Post-Protocol Amendment Patients in the pivotal Cohort 1 of the LEGEND study showed promising efficacy, with 62% of patients remaining in complete response (CR) at six months and all evaluable patients at nine months maintaining CR.
• Detalimogene demonstrated a generally well-tolerated safety profile in Cohort 1, with treatment-related adverse events primarily Grades 1-2 in severity and no Grade 4 or 5 TRAEs reported.
• The product profile of detalimogene is tailored for practical clinical needs, requiring Biosafety Level 1 handling and no ultra-cold chain storage, potentially positioning it as a preferred choice if approved.
• The proprietary DDX gene delivery platform offers payload flexibility and potential for developing new product candidates for various mucosal tissues beyond bladder cancer.
• The company has developed robust, cost-effective, scalable, and patent-protected manufacturing processes for detalimogene.
• Material weaknesses in internal control over financial reporting identified in prior years have been remediated as of October 31, 2025, improving financial reporting reliability.
• Successfully completed an underwritten public offering in November 2025, raising approximately $140.1 million in net proceeds, strengthening liquidity.

Negatives

• Net loss significantly increased to $117.3 million for FY2025 from $55.1 million in FY2024, indicating a substantial increase in operating expenses and cash burn.
• The accumulated deficit reached $372.0 million as of October 31, 2025, reflecting a history of losses and no product revenue since inception.
• Preliminary efficacy data for Pre-Protocol Amendment Patients in the LEGEND study showed a markedly lower 12-month CR rate compared to FDA-approved products for BCG-unresponsive NMIBC patients, raising concerns about the drug's performance under the previous protocol.
• The company is heavily dependent on the success of its single lead product candidate, detalimogene, making it riskier than companies with multiple advanced candidates.
• Significant investments in research and development are expected to continue, leading to anticipated ongoing net losses for the foreseeable future.
• Reliance on third-party contract manufacturers and contract research organizations (CROs) for critical aspects of development and manufacturing introduces supply chain and operational risks.
• The company faces significant competition from larger pharmaceutical and biotechnology companies with greater financial and technical resources, as well as existing FDA-approved treatments for NMIBC.
• Market opportunities for detalimogene may be limited to a small group of patients, and estimates of target patient populations may be inaccurate.
• The company is subject to stringent and evolving data privacy and information security laws, as well as the risk of cyber-attacks, which could result in significant costs and reputational damage.
• As a Canadian company, it is subject to different shareholder protections and additional international operating risks, including currency fluctuations and geopolitical instability.

Risks

• Heavy dependence on the success of detalimogene; clinical trials may not be successful, materially harming the business.
• Significant investments in R&D of detalimogene and other product candidates may not be successful, limiting future profitability.
• Continued net losses and the need to raise additional capital; failure to obtain necessary financing would prevent completion of development and commercialization.
• Estimates of market sizes and forecasts of market growth for product candidates may be inaccurate, adversely affecting business and results of operations.
• Ineffective internal controls over financial reporting or disclosure controls could lead to inaccurate financial reporting or untimely periodic reports.
• Significant competition from other biotechnology and pharmaceutical companies, potentially leading to competitors commercializing products more successfully or earlier.
• Focusing R&D efforts on detalimogene and the DDX platform may lead to foregoing other genetic medicine technologies with greater advantages.
• Detalimogene and the genetic medicine platform are based on novel, unproven technologies, making development time, cost, and regulatory approval unpredictable.
• Development of new therapeutics is a lengthy, expensive, and uncertain process, with risks of additional costs, failure to replicate positive early results, or delays in commercialization.
• Interim, top-line, and preliminary clinical trial data are subject to change as more patient data become available and are subject to audit and verification.
• Difficulties enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Lack of organizational experience in completing later-stage or pivotal clinical trials or submitting a Biologics License Application (BLA).
• Reliance on third parties for manufacturing, development, and testing increases the risk of insufficient quantities, delays, or unacceptable costs.
• Detalimogene is complex to manufacture, and scaling manufacturing capabilities may encounter difficulties, potentially constraining supply or increasing costs.
• Market opportunities for product candidates may be limited to a small group of patients, and estimates of target patient populations may be inaccurate.
• Dependence on the executive team and key personnel; loss of executives or inability to attract/retain highly skilled employees could harm the business.
• Risks related to epidemics and other outbreaks of communicable diseases could significantly disrupt operations, including clinical trials.
• Vulnerability to natural disasters, political crises, acts of terrorism, war, or other catastrophic events.
• Extensive regulation by various U.S. federal and state agencies and non-U.S. regulatory bodies; compliance costs and unpredictable approval processes.
• Regulatory approval may be for a narrower indication than sought or subject to significant limitations.
• Contract manufacturers may not meet or continue to meet regulatory requirements and/or may have limited capacity.
• Drug marketing, price controls, and reimbursement regulations in non-U.S. jurisdictions may materially affect marketability and coverage.
• Global economic uncertainty, changes in geopolitical conditions (e.g., armed conflicts in Russia-Ukraine and the Middle East), and other macroeconomic factors could adversely affect business.
• Inability to obtain and maintain, enforce, and defend patent protection for product candidates or the genetic medicine platform.
• Sales of Common Shares, or the perception of such sales, by the company or Selling Holders could cause the market price to decline.
• Certain existing securityholders acquired securities at prices below current trading prices, and future investors may not experience a similar rate of return.
• There is no assurance that Warrants will be and/or remain in the money prior to their expiration, and they may expire worthless.
• Continued increased costs as a result of operating as a public company, straining resources and diverting management's attention.
• Inability to satisfy Nasdaq's continued listing requirements in the future could limit investor's ability to effect transactions in securities.
• Shareholder protections in Canada differ from those in the United States, and the company is subject to additional risks associated with operating in Canada.
• The Articles and certain Canadian legislation may delay, prevent, or make undesirable an acquisition of all or a significant portion of shares or assets or prevent a change in control.
• Designated specific courts in Canada and the United States as the exclusive forum for certain litigation, which could limit shareholders' ability to obtain a favorable judicial forum.
• Difficulty serving legal process or enforcing judgments against the company due to Canadian incorporation and assets primarily located outside the U.S.
• Ability to use net operating loss carry-forwards and certain other tax attributes may be limited.
• Significant risk of being a Passive Foreign Investment Company (PFIC), which could result in adverse U.S. federal income tax consequences to U.S. Holders.
• Cyber-attacks or other failures in IT systems could result in information theft, data corruption, and significant disruption of business operations.
• Inadequate funding for, or changes in leadership at, the FDA, SEC, and other government agencies could hinder their ability to perform normal functions.
• Employees, independent contractors, and partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards.
• Subject to U.S. and non-U.S. anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations.
• Ongoing healthcare legislative and regulatory reform measures, including drug pricing reforms, may have a material adverse effect on business.
• Product candidates may become subject to unfavorable or unprofitable third-party coverage and reimbursement practices, as well as pricing regulations.
• Guidelines and recommendations published by various organizations (e.g., ICER) may impact the use or reimbursement of detalimogene.
• Inability to protect the confidentiality of trade secrets could adversely affect business and competitive position.
• Third-party claims of intellectual property infringement, misappropriation, or other violation may prevent or delay development and commercialization.
• Claims asserting employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets or claims asserting ownership of intellectual property.
• Intellectual property rights do not necessarily address all potential threats to competitive advantage.
• Inability to protect and enforce trademarks and trade names, or build name recognition in markets of interest.
• Need to grow the size of the organization, both organically and through acquisitions, and potential difficulties in managing this growth.
• Acquisitions, collaborations, or other strategic partnerships may increase capital requirements, dilute shareholders, cause debt, or assume contingent liabilities.

Future Outlook

The company plans to file a Biologics License Application (BLA) with the FDA in the second half of 2026 for detalimogene as a monotherapy to treat BCG-unresponsive NMIBC with CIS. It intends to commercialize detalimogene independently in the United States and selectively partner outside the U.S. The company is also exploring additional clinical applications of detalimogene within high-risk NMIBC and aims to apply its proprietary DDX platform to develop new product candidates for other mucosal tissues. Significant expenses and increasing operating losses are expected for the foreseeable future as clinical development progresses and commercialization infrastructure is established.

Management Comments

• "We believe these updated results illustrate the intended benefits of the protocol amendments."
• "We believe detalimogenes product profile will integrate seamlessly into community urology clinics where the vast majority of urologists practice."
• "We believe our DDX platform has the potential to be the next-generation platform that takes genetic medicine beyond rare diseases and into the mainstream of patient care for larger disease indications."
• "Our management believes that we are not currently involved in any legal proceedings that are likely to have a significant negative effect on our business."
• "We believe that our existing cash and cash equivalents and marketable securities as of October 31, 2025 will be sufficient to fund our operating expenses, debt obligations, and capital expenditure requirements for at least the next 12 months from the issuance date of the consolidated financial statements included within this Annual Report."

Industry Context

The genetic medicine field is nascent and rapidly evolving, with a limited number of FDA or EMA approvals to date. The company operates in a highly competitive biotechnology and pharmaceutical industry, particularly in the development of therapies for non-muscle invasive bladder cancer (NMIBC). There is an urgent unmet medical need for effective intravesical treatments for high-grade NMIBC due to persistent Bacillus Calmette-Gurin (BCG) supply constraints. The FDA has issued guidance to encourage the development of alternative treatments to radical cystectomy, which the company is following. Competitors include established pharmaceutical companies and other biotechnology firms developing both gene-based and non-gene-based therapies for NMIBC.

Comparison to Industry Standards

• Preliminary efficacy data for Pre-Protocol Amendment Patients in the LEGEND study showed a markedly lower 12-month complete response (CR) rate compared to FDA-approved products for BCG-unresponsive NMIBC patients.
• Detalimogene's product profile, requiring Biosafety Level 1 handling and no ultra-cold chain storage, is positioned as a preferred choice compared to other gene therapy products that often have more stringent handling or dosing requirements.
• The updated primary endpoint for Cohort 1 of the LEGEND study (percentage of patients with CR at any time) is consistent with recently approved products for BCG-unresponsive NMIBC registered with the FDA.
• The DDX platform aims to overcome historical challenges faced by genetic medicines, such as immunogenicity, safety concerns, limited efficacy, high cost of goods, and manufacturing difficulties, which are common industry hurdles.

Management Changes

Corporate Governance

Legal Proceedings

• Management believes that the company is not currently involved in any legal proceedings that are likely to have a significant negative effect on its business.

Related Party Transactions

• Lumira Ventures, an entity affiliated with director Gerald Brunk, purchased 800,000 Common Shares for $8.0 million in the February 2024 PIPE Financing.
• An entity affiliated with Forbion European Acquisition Corporation (FEAC), with which directors Wouter Joustra and former director Jasper Bos are general partners, purchased 561,797 Common Shares for approximately $5.0 million in the October 2024 PIPE Financing.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future equity offerings and warrant exercises. The market price of shares is likely to be volatile due to clinical trial results, regulatory approvals, competition, and general market conditions. U.S. holders face a significant risk of adverse tax consequences if the company is deemed a Passive Foreign Investment Company (PFIC).
• **Employees**: Benefit from new equity compensation plans (Amended 2023 Incentive Equity Plan, 2025 ESPP) and inducement grants, which aim to attract and retain highly skilled personnel. However, management changes and departures of key personnel could impact operations and stability.
• **Patients**: Detalimogene aims to address an urgent unmet medical need in BCG-unresponsive NMIBC with CIS, potentially offering a new non-surgical treatment option. The therapy is still in clinical trials, and its ultimate success and availability are uncertain.
• **Creditors (Hercules Capital, Inc.)**: The company has outstanding debt with Hercules Capital, Inc., subject to covenants, but is currently in compliance. The company's ability to meet debt obligations depends on future financing and operational success.
• **Customers (future)**: If approved, detalimogene will be commercialized initially in the U.S., with potential for international partnerships. Market acceptance will depend on efficacy, safety, convenience, price, and reimbursement, impacting future revenue generation.

Next Steps

• Complete the ongoing Phase 2 LEGEND study of detalimogene.
• File a Biologics License Application (BLA) with the FDA in the second half of 2026 for detalimogene as a monotherapy for BCG-unresponsive NMIBC with CIS.
• Commercialize detalimogene independently in the United States, if approved.
• Selectively partner outside of the United States for commercialization of detalimogene.
• Explore additional clinical applications of detalimogene within high-risk NMIBC (e.g., BCG-Nave, BCG-exposed, papillary-only NMIBC).
• Apply the proprietary DDX platform to other mucosal tissues to develop new product candidates.
• Establish medical affairs, sales, marketing, and distribution infrastructure and capabilities to support potential commercial launch.
• Continue to discover and develop additional product candidates.
• Expand headcount to support continued research and development activities.
• Maintain, expand, and enforce the intellectual property portfolio.
• Evaluate the possibility of establishing own manufacturing facilities and capabilities.

Key Dates

Recommendation

The company is in a high-risk, high-reward clinical stage. While the lead product, detalimogene, has received favorable regulatory designations (RMAT, Fast Track, CDRP) and recent Phase 2 data under an amended protocol show promising complete response rates, the significant increase in net losses and accumulated deficit highlight the substantial capital requirements and inherent risks of drug development. The prior data for Pre-Protocol Amendment Patients showing lower CR rates compared to approved products is a concern, even with protocol amendments. The recent capital raise provides liquidity for the near term, but future funding needs are substantial. The stock is highly dependent on successful clinical trial outcomes and regulatory approval, which are uncertain. A 'Hold' recommendation reflects the balance between the potential upside of a successful therapy for an unmet need and the considerable financial and clinical execution risks.

Keywords

Genetic Medicine, Bladder Cancer, NMIBC, Detalimogene, DDX Platform, Clinical Trials, Biotechnology, Oncology, SEC Filing, 10-K, Pharmaceutical, Drug Development, Nasdaq, RMAT, Fast Track, CDRP, Biologics License Application, Financial Report, Corporate Governance, Risk Factors, Intellectual Property, Capital Raise, Immunotherapy, Gene Therapy